Related Experiment Video

Updated: Jul 15, 2026

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Published on: January 5, 2016

Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection

Piotr Nowak¹, Babilonia Barqasho, Anders Sönnerborg

¹Divisions of Clinical Virology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

AIDS (London, England)

|April 7, 2007

Abstract:

High mobility group box protein 1 (HMGB1) is a potent proinflammatory mediator. It has a dichotomic effect on HIV-1 replication in vitro but its role in vivo is unknown. Here we report the novel finding that plasma HMGB1 levels are elevated in HIV-1-infected patients, with the highest concentrations in patients with clinical complications. HMGB1 is likely to contribute to immunoactivation in HIV-1 infection in vivo.

More Related Videos

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Stability of the HIV cascade of care throughout the COVID-19 pandemic in Europe: Results from the multinational EuroSIDA cohort study (2016-2022).

HIV medicine·2026

ClinIAN: Clinically Informed Attention Network.

Bioinformatics advances·2026

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

AIDS (London, England)·2026

Species-level virome profiling reveals compositional differences in the gut prokaryotic DNA virome of people with HIV-1 on antiretroviral therapy.

Gut microbes reports·2026

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro.

Open forum infectious diseases·2026

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

EBioMedicine·2026

See all related articles